TuHURA Biosciences (HURA) News Today $2.70 +0.25 (+10.20%) Closing price 04:00 PM EasternExtended Trading$2.58 -0.12 (-4.44%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock HURA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period TuHURA Biosciences announces executive salary increasesJune 14, 2025 | uk.investing.comWall Street Zen Downgrades TuHURA Biosciences (NASDAQ:HURA) to SellJune 14, 2025 | americanbankingnews.comTuHURA Biosciences (NASDAQ:HURA) Downgraded by Wall Street Zen to "Sell"Wall Street Zen cut TuHURA Biosciences from a "hold" rating to a "sell" rating in a report on Saturday.June 14, 2025 | marketbeat.comTuHURA Biosciences Approves Executive Salary IncreasesJune 12, 2025 | tipranks.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of ShareholdersJune 9, 2025 | prnewswire.comTuHURA Biosciences stock rises following FDA hold liftJune 9, 2025 | au.investing.comTuHURA Biosciences to Continue Carcinoma Drug Trials Following Regulatory Hold LiftJune 9, 2025 | marketwatch.comFDA Clears Path for TuHURA Biosciences (HURA) to Advance Phase 3 Trial | HURA Stock NewsJune 9, 2025 | gurufocus.comFDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for ...June 9, 2025 | gurufocus.comFDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for ...June 9, 2025 | gurufocus.comFDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell CarcinomaJune 9, 2025 | prnewswire.comTuHURA Biosciences: Promising Oncology Advancements and Strategic Acquisitions Drive Buy RatingJune 6, 2025 | tipranks.comTuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer ImmunotherapyJune 3, 2025 | prnewswire.comTuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of ...June 2, 2025 | gurufocus.comTuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual MeetingJune 2, 2025 | prnewswire.comTuHURA Biosciences: Encountering Serious Cash Issues And A Long TimelineMay 28, 2025 | seekingalpha.comQ3 EPS Forecast for TuHURA Biosciences Reduced by AnalystTuHURA Biosciences (NASDAQ:HURA - Free Report) - Research analysts at Zacks Small Cap dropped their Q3 2025 earnings estimates for shares of TuHURA Biosciences in a research report issued on Monday, May 19th. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will earn ($0.1May 24, 2025 | marketbeat.comKineta and TuHURA Biosciences Announce Merger AgreementMay 23, 2025 | tipranks.comEquities Analysts Set Expectations for HURA FY2027 EarningsTuHURA Biosciences (NASDAQ:HURA - Free Report) - Equities research analysts at Zacks Small Cap issued their FY2027 earnings per share estimates for shares of TuHURA Biosciences in a research report issued to clients and investors on Monday, May 19th. Zacks Small Cap analyst J. Vandermosten forecaMay 23, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for HURA FY2025 Earnings?TuHURA Biosciences (NASDAQ:HURA - Free Report) - Stock analysts at HC Wainwright issued their FY2025 earnings estimates for TuHURA Biosciences in a research report issued on Friday, May 16th. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($0.56) per share for theMay 21, 2025 | marketbeat.comHURA: First Quarter 2025 ResultsMay 19, 2025 | finance.yahoo.comTuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate UpdateMay 15, 2025 | prnewswire.comTuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect ConferenceMay 13, 2025 | prnewswire.comTuHURA Biosciences (HURA) Projected to Post Earnings on TuesdayTuHURA Biosciences (NASDAQ:HURA) will be releasing earnings before the market opens on Tuesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-13-tuhura-biosciences-stock/)May 8, 2025 | marketbeat.comKineta Amends Merger Agreement with TuHURA BiosciencesMay 7, 2025 | tipranks.comTuHURA Biosciences, Inc. (HURA)May 6, 2025 | finance.yahoo.comInnovative Immune Therapy Approach Drives Buy Rating for TuHURA BiosciencesMay 6, 2025 | tipranks.comTuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)May 5, 2025 | prnewswire.comGeode Capital Management LLC Buys New Holdings in TuHURA Biosciences (NASDAQ:HURA)Geode Capital Management LLC bought a new stake in shares of TuHURA Biosciences (NASDAQ:HURA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 264,915 shares of the company's stock, valued at apMay 3, 2025 | marketbeat.comTuHURA And Kineta Present Updated Results From Phase I-II Study Of KVA12123April 30, 2025 | nasdaq.comTuHURA Biosciences: Promising Developments in Anti-VISTA Antibody and DNA-based Immune Activator Justify Buy RatingApril 29, 2025 | tipranks.comTuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure ...April 29, 2025 | seekingalpha.comTuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual MeetingApril 28, 2025 | prnewswire.comIs TuHURA Biosciences, Inc. (HURA) the Best Rising Penny Stock to Buy According to Analysts?April 18, 2025 | insidermonkey.comZacks Small Cap Issues Positive Forecast for HURA EarningsTuHURA Biosciences (NASDAQ:HURA - Free Report) - Equities research analysts at Zacks Small Cap increased their Q3 2025 earnings estimates for TuHURA Biosciences in a research report issued to clients and investors on Monday, April 14th. Zacks Small Cap analyst J. Vandermosten now expects that theApril 18, 2025 | marketbeat.comHURA: 2024 Financial ResultsApril 14, 2025 | msn.comTuHURA Biosciences hires new EVP for drug developmentApril 9, 2025 | uk.investing.comTuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual MeetingApril 8, 2025 | prnewswire.comQ2 EPS Estimate for TuHURA Biosciences Increased by AnalystTuHURA Biosciences (NASDAQ:HURA - Free Report) - Stock analysts at HC Wainwright upped their Q2 2026 earnings per share (EPS) estimates for TuHURA Biosciences in a research note issued on Thursday, April 3rd. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per sApril 8, 2025 | marketbeat.comTuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program ManagementApril 7, 2025 | prnewswire.comEquities Analysts Set Expectations for HURA Q3 EarningsTuHURA Biosciences (NASDAQ:HURA - Free Report) - Equities research analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for TuHURA Biosciences in a report issued on Thursday, April 3rd. HC Wainwright analyst R. Burns forecasts that the company will earn ($0.10) per shApril 6, 2025 | marketbeat.comHC Wainwright Cuts TuHURA Biosciences (NASDAQ:HURA) Price Target to $12.00HC Wainwright cut their price objective on shares of TuHURA Biosciences from $13.00 to $12.00 and set a "buy" rating for the company in a report on Thursday.April 5, 2025 | marketbeat.comIs TuHURA Biosciences (NASDAQ:HURA) In A Good Position To Deliver On Growth Plans?April 2, 2025 | finance.yahoo.comTuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate UpdateApril 1, 2025 | prnewswire.comTuHURA Biosciences (NASDAQ:HURA) Stock Price Up 1.7% - Still a Buy?TuHURA Biosciences (NASDAQ:HURA) Shares Up 1.7% - Should You Buy?March 28, 2025 | marketbeat.comTuHURA Biosciences Announces Acquisition of Kineta, Inc.March 18, 2025 | msn.comTuHURA Biosciences appoints Craig Tendler to board of directorsMarch 11, 2025 | markets.businessinsider.comTuHURA Biosciences, Inc. to Present at the 37th Annual ROTH ConferenceMarch 10, 2025 | gurufocus.comQ2 Earnings Estimate for HURA Issued By HC WainwrightTuHURA Biosciences (NASDAQ:HURA - Free Report) - Equities researchers at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of TuHURA Biosciences in a report issued on Monday, March 3rd. HC Wainwright analyst R. Burns expects that the company will earn ($0.20) per share foMarch 7, 2025 | marketbeat.comTuHURA Biosciences initiated with a Buy at H.C. WainwrightMarch 4, 2025 | markets.businessinsider.com Get TuHURA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HURA and its competitors with MarketBeat's FREE daily newsletter. Email Address HURA Media Mentions By Week HURA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HURA News Sentiment▼0.210.56▲Average Medical News Sentiment HURA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HURA Articles This Week▼42▲HURA Articles Average Week Get TuHURA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HURA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ZVRA News Today ABVX News Today ATYR News Today TRML News Today AMLX News Today ALT News Today RGNX News Today ORKA News Today RAPP News Today ERAS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HURA) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump's crypto revolution is now fully underway and now, we believe he’s about to deliver on his biggest promi...Crypto 101 Media | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TuHURA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TuHURA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HURA Stock Free HURA Stock Alerts